Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4 studies found for:    "methodist hospital" | Open Studies | "Lymphoma, B-Cell" | United States, Texas | Houston
Show Display Options
Rank Status Study
1 Recruiting Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Conditions: Lymphoma;   Myeloma;   Leukemia
Intervention: Biological: Kappa CD28 T cells
2 Recruiting Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Conditions: Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Acute Lymphocytic Leukemia
Intervention: Biological: CD19 Specific CAR T Cells
3 Recruiting Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
Conditions: Stage II Diffuse Large B-Cell Lymphoma;   Stage III Diffuse Large B-Cell Lymphoma;   Stage IV Diffuse Large B-Cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
4 Recruiting A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)
Conditions: Refractory Diffuse Large B Cell Lymphoma;   Refractory Primary Mediastinal B Cell Lymphoma;   Refractory Transformed Follicular Lymphoma
Intervention: Biological: KTE-C19

Indicates status has not been verified in more than two years